Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MPL | P40238 | 4/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868647 | 0.86 | ROCK1 (0.50) | CYP1A2CYP2C9CLK4NPC1RAB9A | |
| SCHEMBL11317380 | 0.82 | MEN1 (0.55) | CYP1A2CYP2C9CLK4NPC1RAB9A | |
| SCHEMBL4724653 | 0.81 | NPC1 (0.55) | AURKACYP1A2CYP2C9CLK4NPC1 | |
| SCHEMBL4872523 | 0.78 | NPC1 (0.57) | AURKACYP1A2CYP2C9CLK4NPC1 | |
| SCHEMBL5244511 | 0.77 | NPC1 (0.56) | AURKACYP1A2CYP2C9CLK4NPC1 | |
| SCHEMBL4873164 | 0.71 | MPL (0.55) | NPC1RAB9AMPLLCKEGFR | |
| SCHEMBL4865217 | 0.71 | SMN1; SMN2 (0.55) | AURKANPC1RAB9AMPLAURKB | |
| SCHEMBL4877863 | 0.71 | S1PR1 (0.46) | AURKANPC1RAB9AAURKBEGFR | |
| SCHEMBL28001138 | 0.71 | ABL1 (0.67) | CYP1A2CYP2C9CLK4EGFRERBB3 | |
| SCHEMBL4878410 | 0.71 | AURKA (0.60) | AURKANPC1RAB9AMPLAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | AURKA 4299/4885CYP1A2 1892/4885CYP2C9 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.